Pharmacokinetics of Dextran-70 in patients with cirrhosis and ascites undergoing therapeutic paracentesis

Pharmacological studies of RGTA11, a heparan sulfate mimetic polymer, efficient on muscle regeneration

“…administration. [20][21][22] In our experiments, H 3 -RGTA 11 was injected at tracer doses and it was not possible to obtain specific activities with tritium that permitted an injection of effective pharmacological doses. The proportion of labeled material stuck in the injured muscle was still too small to make a difference detectable at the plasma level when compared to healthy controls.…”

Novel carbonyl-group-containing dextran synthesis by pyranose-2-oxidase and dextransucrase

“…[1][2][3] In particular, dextran, consisting of glucose units linked mainly by a-(1,6) glycoside bonds, has been widely developed in analytical engineering and the pharmaceutical industry as well as in biochemical engineering owing to the hydrophilicity of plural hydroxyl groups and the flexibility of dextran backbone from random structure. For example, a solution of dextran with a molecular weight of 75-100 kDa is used in transfusion as a blood-plasma volume expander, 4 and cross-linked dextran is used as a packed bed in a column to separate and purify molecules with molecular weights in the range of 0.7-200 kDa. 5,6 Traditionally, the modification of dextran has involved the direct introduction of a functional group into the dextran backbone via chemical reaction.…”

Excipient pharmacokinetics and profiling

“…Data collected from (ACS, 2014; Arturson et al, 1971;Klotz and Kroemer, 1987;Mehvar et al, 1995;Mehvar and Shepard, 1992;Terg et al, 1996). 1.9 42 67 V D (L/kg) 0.14 0.10 composition will affect their pharmacokinetics.…”